Clinical trial

Speech, Linguistic and Acoustic Markers in Parkinson's Disease

Name

H00011523

Description

The Investigators aim to identify speech and language markers that provide information on cognitive function and predict cognitive decline in Parkinson's disease. The Investigators will administer speech tasks and cognitive assessments to participants with Parkinson's disease and healthy controls. The Investigators will also explore the associations between genetic factors and speech and cognitive status in Parkinson's disease.

Trial arms

Trial start

2020-01-13

Estimated PCD

2023-09-01

Trial end

2025-02-01

Status

Active (not recruiting)

Treatment

Cognitive Battery

Participants will be asked to complete a series of cognitive testing (testing of concentration, memory, and other thinking abilities).

Arms:

Control, Parkinson's Disease

Voice, Speech and Language Analysis

Participants will be asked to perform speaking and reading tasks, which will be recorded. Participants will be asked to complete a laptop-based test of language comprehension.

Arms:

Control, Parkinson's Disease

Questionnaires and Clinical Assessments

Participants with Parkinson's disease will complete an examination of their symptoms and questionnaires assessing disease symptoms, mood and activities of daily living. Healthy controls participants will be asked to complete questionnaires on mood.

Arms:

Control, Parkinson's Disease

DNA Analysis

Participants will have their blood drawn for DNA analysis.

Arms:

Parkinson's Disease

Size

Primary endpoint

Detection of speech acoustic parameters that classify PD participants by cognitive status (mild cognitive impairment [MCI] vs. normal cognition)

12-24 months

Duration and location of pauses during speech in PD participants with and without mild cognitive impairment

12-24 months

Syntax processing efficiency score (percentage correctly understood sentences/processing time) in controls, and in PD with and without MCI

12-24 months

Eligibility criteria

Inclusion Criteria: * Parkinson's Disease (or healthy control) * Disease duration ≥ 2 years * Mild cognitive impairment or normal cognition Exclusion Criteria: * Diagnosis of dementia (MoCA \<21) * Adults unable to consent * Age \< 18 * Pregnant women * Prisoners * Non-English speakers * Any neurological disorder other than PD * Deep brain stimulator placement * Severe, unstable psychiatric disorder * Unintelligible speech due to effects of PD * Visual acuity or color vision impairment that would interfere with cognitive testing * Other voice, speech or swallowing disorders or history of surgery involving palate/nasopharynx/larynx/vocal cords

Protocol

{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'CROSS_SECTIONAL'}, 'bioSpec': {'retention': 'SAMPLES_WITH_DNA', 'description': 'Blood samples'}, 'enrollmentInfo': {'count': 70, 'type': 'ESTIMATED'}}

Updated at

2024-05-14

1 organization

Organization

University of Massachusetts, Worcester